ClinicalTrials.gg
CompletedNCT07843667Updated Sep 28, 2026

Pulmonary and Musculoskeletal Impairments in Parkinson's Patients

An observational study in Parkinson Disease, sponsored by Izmir Democracy University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Izmir Democracy University · Observational

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.

Enrollment
65th of 73
30 · median 61
Started
2023
with 20 others
Observational
73 of 172
23 open now
Registered
168th of 172
by date

Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 65th largest by enrollment of the 73 observational ones that give a count, is one of 21 that started in 2023, is one of 73 observational ones, and was the 168th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Parkinson Disease with a site in Turkey, or all of them as a file.
02

Study summary

In this study, the relationships between pain severity, chest mobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's disease patients will be investigated.

Read the detailed description

In patients with Parkinson's disease, motor and non-motor symptoms can vary depending on physical inactivity, the nature of the disease, and its treatment. The relationships between pain, chest wall immobility, cough strength, muscle strength, physical activity levels, and quality of life in Parkinson's patients have not yet been fully elucidated in the literature. Therefore, this study aims to shed light on this subject.

03

Conditions studied

  • Parkinson Disease

Keywords

  • pain
  • chest mobility
  • muscle strength
  • physical activity
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

At least 30 Parkinson's patients will be included in the analyses.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being over 18 years old,
  • Volunteering to participate in the research,
  • Being diagnosed with Parkinson's disease
  • Comorbid conditions (such as hypertension, diabetes) are under control
  • Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
  • Having the ability to ambulate and walk independently
  • Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Exclusion criteria

Exclusion criteria for Parkinson's patients;

  • Sudden drug or dose change during the study period
  • A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
  • Having had myocardial infarction and pulmonary embolism in the last 30 days,
  • Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
  • Having severe vision loss or vestibular dysfunction
  • Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on , with a history of shortness of breath and/or palpitation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Parkinson's disease group

    This group will consist of individuals with Parkinson disease.

    Other: Physical Evaluations of Individuals with Parkinson's Disease

Interventions

  • OtherPhysical Evaluations of Individuals with Parkinson's Disease

    In this study, data regarding chest mobility, cough strength, muscle strength, physical activity, and quality of life-collected from Parkinson's patients via face-to-face interviews-will be analyzed. The data for all these assessments were collected in a single session lasting a maximum of approximately one hour. Step counts for each individual were tracked using a pedometer over a period of three days.

06

What researchers measure

Primary outcomes

  1. Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire.

    The status of quality of life was evaluated using Parkinson's Disease Questionnaire (PDQ-39) questionnaire. Parkinson's Disease Questionnaire-39 (PDQ39) is a 39-item quality of life questionnaire. Evaluation for each question item ranges from 0 (no problem) to 4 (constant problem). Low scores in total indicate an improvement in people's quality of life.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Cough Strength

    Cough Strength was evaluated using a Peak Flow Meter.

    Time frame: through study completion, an average of 1 year

  2. Daily average step count

    Daily average step counts were recorded via a pedometer everyday within 3 days after confirming enrolment. All individuals will be asked to carry their pedometers with them during the day and record to their diaries.

    Time frame: through study completion, an average of 1 year

  3. Hand grip strength

    Hand grip strength was evaluated using a hand dynamometer.

    Time frame: through study completion, an average of 1 year

  4. Chest mobility

    Chest mobility was evaluated using a tape measure.

    Time frame: through study completion, an average of 1 year

  5. Cognitive status

    Cognitive state will be evaluated using The mini-mental state examination (MMSE). It is an 11 question test. The highest score from the test is 30 points. Scores of 23 and lower indicate cognitive dysfunction, and scores of 24 and higher indicate normal cognitive level.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Izmir Democracy University
    Izmir, 35140, Turkey (Türkiye)
08

References and documents

Publications

  • Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic. Mov Disord. 2020 Jul;35(7):1097-1099. doi: 10.1002/mds.28134. Epub 2020 Jun 7. No abstract available. PubMed 32428342 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Aug 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartActual
May 13, 2023
Primary completionActual
Aug 30, 2024
CompletionActual
Dec 30, 2024
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843667
Lead sponsor
Izmir Democracy University
Responsible party
Gulsah Bargi (Principal Investigator, Izmir Democracy University) — Principal investigator
First posted
Sep 28, 2026
Start date
May 13, 2023
Primary completion
Aug 30, 2024
Completion
Dec 30, 2024
Last update
Sep 28, 2026

Study contacts

GÜLŞAH BARĞI, Assoc Prof
study director · Izmir Democracy University
MERVE ŞAHİN
principal investigator · Izmir Democracy University
ÖZLEM ÇİNAR ÖZDEMİR
principal investigator · Abant Izzet Baysal University
YASEMİN ÜNAL
principal investigator · Bandirma Health Practice and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion